Cargando…
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy
Immune checkpoint inhibitors have revolutionized treatment and outcome of melanoma and many other solid malignancies including non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Unfortunately, only a minority of patients have a long-term benefit, while the remaining demonstrate prima...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349154/ https://www.ncbi.nlm.nih.gov/pubmed/32353934 http://dx.doi.org/10.3390/vaccines8020203 |
_version_ | 1783556996646043648 |
---|---|
author | Botticelli, Andrea Cirillo, Alessio Scagnoli, Simone Cerbelli, Bruna Strigari, Lidia Cortellini, Alessio Pizzuti, Laura Vici, Patrizia De Galitiis, Federica Di Pietro, Francesca Romana Cerbelli, Edoardo Ghidini, Michele D’Amati, Giulia Della Rocca, Carlo Mezi, Silvia Gelibter, Alain Giusti, Raffaele Cortesi, Enrico Ascierto, Paolo Antonio Nuti, Marianna Marchetti, Paolo |
author_facet | Botticelli, Andrea Cirillo, Alessio Scagnoli, Simone Cerbelli, Bruna Strigari, Lidia Cortellini, Alessio Pizzuti, Laura Vici, Patrizia De Galitiis, Federica Di Pietro, Francesca Romana Cerbelli, Edoardo Ghidini, Michele D’Amati, Giulia Della Rocca, Carlo Mezi, Silvia Gelibter, Alain Giusti, Raffaele Cortesi, Enrico Ascierto, Paolo Antonio Nuti, Marianna Marchetti, Paolo |
author_sort | Botticelli, Andrea |
collection | PubMed |
description | Immune checkpoint inhibitors have revolutionized treatment and outcome of melanoma and many other solid malignancies including non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Unfortunately, only a minority of patients have a long-term benefit, while the remaining demonstrate primary or acquired resistance. Recently, it has been demonstrated that the prevalence of programmed death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) varies based on the anatomical site of metastases. In particular, liver seems to have more immunosuppressive microenvironment while both the presence of lymph nodal disease and lung metastases seem to have the highest prevalence of PD-L1 and TILs. The aim of the present study is to investigate the possible role of site of metastases as a predictive factor for response or resistance to immunotherapy in several types of cancer. In this multicenter retrospective study, we enrolled patients with metastatic NSCLC, melanoma, RCC, urothelial, merkel carcinoma, and colon cancer who received immunotherapy from April 2015 to August 2019. Major clinicopathological parameters were retrieved and correlated with patients’ survival outcomes in order to assess their prognostic value and build a useful tool to assist in the decision-making process. A total of 291 patients were included in this study. One hundred eighty-seven (64%) patients were male and 104 (36%) female. The tumor histology was squamous NSCLC in 56 (19%) patients, non-squamous NSCLC in 99 (34%) patients, melanoma in 101 (35%) patients, RCC in 28 (10%) patients, and other tumors in the remaining 7 (2%) patients. The number of metastatic sites was 1 in 103 patients (35%), 2 in 104 patients (36%) and 3 in 84 patients (29%). Out of 183 valuable patients, the entity of response was complete response (CR), partial response (PR), stable disease (SD), and progression disease (PD) in 15, 53, 31, and 79 patients, respectively. Using an univariate analysis (UVA), tumor burden (p = 0.0004), the presence of liver (p = 0.0009), bone (p = 0.0016), brain metastases (p < 0.0001), the other metastatic sites (p = 0.0375), the number of metastatic sites (p = 0.0039), the histology (p = 0.0034), the upfront use of immunotherapy (p = 0.0032), and Eastern Cooperative Oncology Group (ECOG) Perfomance status (PS) ≥ 1 (p < 0.0001) were significantly associated with poor overall survival (OS). Using a multivariate analysis (MVA) the presence of liver (p = 0.0105) and brain (p = 0.0026) metastases, the NSCLC diagnosis (p < 0.0001) and the ECOG PS (p < 0.0001) resulted as significant prognostic factors of survival. Regarding the progression free survival (PFS), using a UVA of the tumor burden (p = 0.0004), bone (p = 0.0098) and brain (p = 0.0038) metastases, the presence of other metastatic sites (p = 0.0063), the number of metastatic sites (p = 0.0007), the histology (p = 0.0007), the use of immunotherapy as first line (p = 0.0031), and the ECOG PS ≥ 1 (p ≤ 0.0001) were associated with a lower PFS rate. Using an MVA, the presence of brain (p = 0.0088) and liver metastases (p = 0.024) and the ECOG PS (p < 0.0001) resulted as predictors of poor PFS. Our study suggests that the site of metastases could have a role as prognostic and predictive factor in patients treated with immunotherapy. Indeed, regardless of the histology, the presence of liver and brain metastases was associated with a shorter PFS and OS, but these results must be confirmed in further studies. In this context, a deep characterization of microenvironment could be crucial to prepare patients through novel strategies with combination or sequential immunotherapy in order to improve treatment response. |
format | Online Article Text |
id | pubmed-7349154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73491542020-07-22 The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy Botticelli, Andrea Cirillo, Alessio Scagnoli, Simone Cerbelli, Bruna Strigari, Lidia Cortellini, Alessio Pizzuti, Laura Vici, Patrizia De Galitiis, Federica Di Pietro, Francesca Romana Cerbelli, Edoardo Ghidini, Michele D’Amati, Giulia Della Rocca, Carlo Mezi, Silvia Gelibter, Alain Giusti, Raffaele Cortesi, Enrico Ascierto, Paolo Antonio Nuti, Marianna Marchetti, Paolo Vaccines (Basel) Article Immune checkpoint inhibitors have revolutionized treatment and outcome of melanoma and many other solid malignancies including non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Unfortunately, only a minority of patients have a long-term benefit, while the remaining demonstrate primary or acquired resistance. Recently, it has been demonstrated that the prevalence of programmed death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) varies based on the anatomical site of metastases. In particular, liver seems to have more immunosuppressive microenvironment while both the presence of lymph nodal disease and lung metastases seem to have the highest prevalence of PD-L1 and TILs. The aim of the present study is to investigate the possible role of site of metastases as a predictive factor for response or resistance to immunotherapy in several types of cancer. In this multicenter retrospective study, we enrolled patients with metastatic NSCLC, melanoma, RCC, urothelial, merkel carcinoma, and colon cancer who received immunotherapy from April 2015 to August 2019. Major clinicopathological parameters were retrieved and correlated with patients’ survival outcomes in order to assess their prognostic value and build a useful tool to assist in the decision-making process. A total of 291 patients were included in this study. One hundred eighty-seven (64%) patients were male and 104 (36%) female. The tumor histology was squamous NSCLC in 56 (19%) patients, non-squamous NSCLC in 99 (34%) patients, melanoma in 101 (35%) patients, RCC in 28 (10%) patients, and other tumors in the remaining 7 (2%) patients. The number of metastatic sites was 1 in 103 patients (35%), 2 in 104 patients (36%) and 3 in 84 patients (29%). Out of 183 valuable patients, the entity of response was complete response (CR), partial response (PR), stable disease (SD), and progression disease (PD) in 15, 53, 31, and 79 patients, respectively. Using an univariate analysis (UVA), tumor burden (p = 0.0004), the presence of liver (p = 0.0009), bone (p = 0.0016), brain metastases (p < 0.0001), the other metastatic sites (p = 0.0375), the number of metastatic sites (p = 0.0039), the histology (p = 0.0034), the upfront use of immunotherapy (p = 0.0032), and Eastern Cooperative Oncology Group (ECOG) Perfomance status (PS) ≥ 1 (p < 0.0001) were significantly associated with poor overall survival (OS). Using a multivariate analysis (MVA) the presence of liver (p = 0.0105) and brain (p = 0.0026) metastases, the NSCLC diagnosis (p < 0.0001) and the ECOG PS (p < 0.0001) resulted as significant prognostic factors of survival. Regarding the progression free survival (PFS), using a UVA of the tumor burden (p = 0.0004), bone (p = 0.0098) and brain (p = 0.0038) metastases, the presence of other metastatic sites (p = 0.0063), the number of metastatic sites (p = 0.0007), the histology (p = 0.0007), the use of immunotherapy as first line (p = 0.0031), and the ECOG PS ≥ 1 (p ≤ 0.0001) were associated with a lower PFS rate. Using an MVA, the presence of brain (p = 0.0088) and liver metastases (p = 0.024) and the ECOG PS (p < 0.0001) resulted as predictors of poor PFS. Our study suggests that the site of metastases could have a role as prognostic and predictive factor in patients treated with immunotherapy. Indeed, regardless of the histology, the presence of liver and brain metastases was associated with a shorter PFS and OS, but these results must be confirmed in further studies. In this context, a deep characterization of microenvironment could be crucial to prepare patients through novel strategies with combination or sequential immunotherapy in order to improve treatment response. MDPI 2020-04-28 /pmc/articles/PMC7349154/ /pubmed/32353934 http://dx.doi.org/10.3390/vaccines8020203 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Botticelli, Andrea Cirillo, Alessio Scagnoli, Simone Cerbelli, Bruna Strigari, Lidia Cortellini, Alessio Pizzuti, Laura Vici, Patrizia De Galitiis, Federica Di Pietro, Francesca Romana Cerbelli, Edoardo Ghidini, Michele D’Amati, Giulia Della Rocca, Carlo Mezi, Silvia Gelibter, Alain Giusti, Raffaele Cortesi, Enrico Ascierto, Paolo Antonio Nuti, Marianna Marchetti, Paolo The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy |
title | The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy |
title_full | The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy |
title_fullStr | The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy |
title_full_unstemmed | The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy |
title_short | The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy |
title_sort | agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349154/ https://www.ncbi.nlm.nih.gov/pubmed/32353934 http://dx.doi.org/10.3390/vaccines8020203 |
work_keys_str_mv | AT botticelliandrea theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT cirilloalessio theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT scagnolisimone theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT cerbellibruna theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT strigarilidia theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT cortellinialessio theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT pizzutilaura theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT vicipatrizia theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT degalitiisfederica theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT dipietrofrancescaromana theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT cerbelliedoardo theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT ghidinimichele theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT damatigiulia theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT dellaroccacarlo theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT mezisilvia theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT gelibteralain theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT giustiraffaele theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT cortesienrico theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT asciertopaoloantonio theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT nutimarianna theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT marchettipaolo theagnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT botticelliandrea agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT cirilloalessio agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT scagnolisimone agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT cerbellibruna agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT strigarilidia agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT cortellinialessio agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT pizzutilaura agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT vicipatrizia agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT degalitiisfederica agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT dipietrofrancescaromana agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT cerbelliedoardo agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT ghidinimichele agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT damatigiulia agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT dellaroccacarlo agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT mezisilvia agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT gelibteralain agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT giustiraffaele agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT cortesienrico agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT asciertopaoloantonio agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT nutimarianna agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy AT marchettipaolo agnosticroleofsiteofmetastasisinpredictingoutcomesincancerpatientstreatedwithimmunotherapy |